Biogen (BIIB) Land & Improvements (2009 - 2010)
Biogen (BIIB) posted quarterly Land & Improvements of $107.6 million for Q4 2010, down 3.24% year-over-year from $111.2 million in Q4 2009, and down 3.24% quarter-over-quarter from $111.2 million in Q4 2009.
Biogen (BIIB) Land & Improvements (2009 - 2010) Analysis & Trends
Biogen's Land & Improvements history runs 2 years deep, the most recent figure standing at $107.6 million for Q4 2010.
- In Q4 2010, Land & Improvements fell 3.24% year-over-year to $107.6 million; the TTM figure through Dec 2010 stood at $107.6 million (down 3.24% YoY), while the FY2010 annual figure was $107.6 million, down 3.24% from the prior year.
- Land & Improvements for Q4 2010 stood at $107.6 million, down from $111.2 million in the prior quarter.
- The five-year high for Land & Improvements was $111.2 million in Q4 2009, with the low at $107.6 million in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 107.60 Mn |
| Dec 31, 2009 | 111.20 Mn |